Article Information
History
- November 15, 2024.
Copyright
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY 4.0 International license.
Author Information
- Ami Kawamoto1,
- Masahiro Hashida1,
- Katsuyasu Ishida1,
- Kei Furihata2,
- Aisaku Ota2,
- Kaori Takahashi1,
- Sachiko Sakakibara1,
- Takashi Nakano3 and
- Fumihiko Takeshita1,*
- 1R&D Division, Daiichi Sankyo Co., Ltd., Tokyo, Japan
- 2Global DX, Daiichi Sankyo Co., Ltd., Tokyo, Japan
- 3Department of Pediatrics, Kawasaki Medical School, Okayama, Japan
- ↵*Corresponding author:
Fumihiko Takeshita, 1-16-13, Kitakasai, Edogawa-ku, Tokyo 134-0081, Japan, Tel: +81-3-3680-0151, Fax: +81-3-5696-7346, E-mail: fumihiko.takeshita{at}daiichisankyo.com
Posted November 15, 2024.
Immunogenicity and safety of DS-5670d, an mRNA-based COVID-19 vaccine targeting omicron XBB.1.5: Results from a phase 3, randomized, active-controlled study in adults and children aged ≥12 years
